PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues

Nick Beije; Wassim Abida; Emmanuel S Antonarakis; Elena Castro; Ronald de Wit; Karim Fizazi; Silke Gillessen; Maha Hussain; Joaquin Mateo; Michael J Morris; David Olmos; Oliver Sartor; Adam Sharp; Christopher J Sweeney; Johann S de Bono

doi:10.1016/j.eururo.2023.03.038

PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues

Eur Urol. 2023 Sep;84(3):253-256. doi: 10.1016/j.eururo.2023.03.038. Epub 2023 Apr 20.

Authors

Affiliations

¹ The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, Sutton, UK.
² Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
³ Department of Medicine, University of Minnesota, Minneapolis, MN, USA.
⁴ Department of Medical Oncology, Hospital Universitario 12 de Octubre, Instituto de Investigación Sanitaria Hospital 12 de Octubre, Madrid, Spain.
⁵ Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
⁶ Institut Gustave Roussy, University of Paris-Saclay, Villejuif, France.
⁷ Istituto Oncologico della Svizzera Italiana, Ente Ospedaliero Cantonale Bellinzona, Bellinzona, Switzerland.
⁸ Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
⁹ Vall d'Hebron Institute of Oncology, Barcelona, Spain.
¹⁰ Tulane Cancer Center, Tulane University Medical School, New Orleans, LA, USA.
¹¹ South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia.
¹² The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, Sutton, UK. Electronic address: johann.de-bono@icr.ac.uk.

PMID: 37087376
DOI: 10.1016/j.eururo.2023.03.038

Abstract

The combination of PARP and androgen receptor signalling inhibitors is best reserved for cases for which we expect an overall survival benefit on the basis of disease biology. The data to date should encourage us to perform more, not less, testing for DNA repair defects.

Keywords: Androgen receptor signalling inhibitor; Castration-resistant prostate cancer; Metastatic prostate cancer; PARP inhibitor.

Publication types

Editorial

MeSH terms

DNA Repair
Humans
Male
Poly(ADP-ribose) Polymerase Inhibitors* / pharmacology
Poly(ADP-ribose) Polymerase Inhibitors* / therapeutic use
Prostatic Neoplasms, Castration-Resistant* / drug therapy
Prostatic Neoplasms, Castration-Resistant* / genetics
Signal Transduction

Substances

Poly(ADP-ribose) Polymerase Inhibitors

Grants and funding

MR/W018217/1/MRC_/Medical Research Council/United Kingdom